TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05483894
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
Study: NCT00000865
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000865
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000865
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000865
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000865
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002094
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04481113
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04481113
Drug: Niraparib Tosylate Monohydrate
Normalized name: Niraparib tosylate monohydrate
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04525547
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib
Study: NCT05713006
Drug: Alectinib Oral Product
Normalized name: alectinib Oral Product
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
Study: NCT06139419
Drug: concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
Study: NCT06139419
Drug: Immunotheapy consolidation
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
Study: NCT06139419
Drug: Thymosin Alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months.
Study: NCT05242874
Drug: Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
Study: NCT05795920
Drug: Utidelone injection in combination with gemcitabine
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
Study: NCT04789174
Drug: Solriamfetol
Normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solriamfetol 75 mg/d Solriamfetol 150 mg/d
Study: NCT04912765
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
Study: NCT04108858
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05596006
Drug: Domperidon
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone capsule 10 mg
Study: NCT03083431
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
Study: NCT03780127
Drug: Fenfluramine Hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
Study: NCT05600062
Drug: Racecadotril 100 milligram (MG) Oral Capsule
Normalized name: racecadotril 100 MG
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed NEP inhibitor
Study: NCT05745467
Drug: Povidone Iodine 5% Soln,Top,Kit
Normalized name: POVIDONE IODINE 5% SOLN,TOP,KIT
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% povidone iodine will be swabbed in patients nares of the experimental group.
Study: NCT04436458
Drug: Niclosamide Oral Tablet
Normalized name: niclosamide Oral Tablet
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued SOC therapy together with niclosamide TID for 14 days
Study: NCT04939753
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administration to sedate the patient
Study: NCT06671587
Drug: iGlarLixi (insulin glargine/lixisenatide)
Normalized name: INSULIN GLARGINE/LIXISENATIDE
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~- iGlarLixi must not be mixed with other insulins nor diluted.
Study: NCT06671587
Drug: Gla-100 (insulin glargine)
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
Study: NCT05796271
Drug: R-Chop and Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
Study: NCT04860960
Drug: Hydroxypropyl-beta-cyclodextrin
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose is 2000 mg/kg body weight provided every 2 weeks intravenously
Study: NCT05654090
Drug: cefoperazone sodium and sulbactam sodium
Normalized name: Cefoperazone Sodium
DrugBank: Cefoperazone (DB01329)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetic study under fasting conditions
Study: NCT04984278
Drug: Nabiximols
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oromucosal spray
Study: NCT06153706
Drug: Subgingival application of L-PRF loaded with metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
Study: NCT05431322
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
Study: NCT06294665
Drug: Pericapsular Nerve Group (PENG) Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The PENG block will be performed ,the patient is placed in the supine position , the procedural leg is slightly abducted, the curvilinear low-frequency ultrasound probe will be placed over the line parallel to the inguinal ligament. It will subsequently rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration, by one of the two syringes each one has a serial number corresponding to each group.
Study: NCT05716425
Drug: STI-1558
Normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
Study: NCT05710094
Drug: SoftOx Biofilm Eradicator (Groups 1 to 7)
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
Study: NCT05038202
Drug: Bencycloquidium Bromide Nasal Spray
Normalized name: ipratropium bromide Metered Dose Nasal Spray
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis.
Study: NCT05038202
Drug: Mometasone Furoate Aqueous Nasal Spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment.
Study: NCT03390530
Drug: Thyroxine
Normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 µg/kg/day divided into two doses intravenous every 12 hours
Study: NCT05301062
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Radium-223 should follow the approved local product information according to National Medical Products Administration (NMPA) approved label
Study: NCT05326763
Drug: Platelet Rich Plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing 2 mL of PRP with concentration of 4-6 times the average normal values, 20mL of blood will be first collected from the patient's upper limb cubital vein using an 18G needle. A local subcutaneous anesthesia (2 ml of 1% lidocaine) will be finished by the orthopedist.
Study: NCT06108739
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
Study: NCT06108739
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 10mg/kg ATG was administered.
Study: NCT00002396
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04191447
Drug: Flamboyant 200/12
DrugBank: Lamb (DB10537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flamboyant 200/12 capsule
Study: NCT04191447
Drug: Budesonide / Formoterol 400/12
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide / Formoterol 400/12 capsule
Study: NCT03542695
Drug: Copper Cu-64-DOTA-alendronate
Normalized name: COPPER CU-64
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06519448
Drug: Empagliflozin 10 miligrams (mg)
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Use of empagliflozin 10 mg daily for 12 months.
Study: NCT05388058
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied topically
Study: NCT05667909
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
Study: NCT05787613
Drug: HLX26
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-LAG-3 monoclonal Antibody Injection
Study: NCT05787613
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 humanized monoclonal antibody injection
Study: NCT05787613
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
Study: NCT04797182
Drug: avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: avatrombopag,60 mg/d,po
Study: NCT06332612
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
Study: NCT04395183
Drug: 5-Hydroxytryptophan 100 MG
Normalized name: 5-hydroxytryptophan 100 MG
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-HTP 100mg PO BID
Study: NCT06332612
Drug: betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1will recieve topical cream betamethasone thrice daily
Study: NCT06332612
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 will receive Pentoxifylline tablet 400 mg twice daily
Study: NCT06100692
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients will receive a 30 pts a combination of oral vit D and zinc
Study: NCT03289325
Drug: dexmedetomidine hydrochloride for injection
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation.
Study: NCT04701918
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection through a vein (IV) every 3 weeks
Study: NCT04701918
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection through a vein (IV) every 2 weeks
Study: NCT04566133
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally 2 mg once a day
Study: NCT04566133
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally 600 mg twice a day-1,200 mg total dose
Study: NCT05791890
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: observational study to evaluate the incidence of infections during therapy with Gilteritinb
Study: NCT05167175
Drug: Olaparib tablet
Normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
Study: NCT05167175
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
Study: NCT05167175
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone Tablets should be taken 5 mg once daily.
Study: NCT06628778
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
Study: NCT05205317
Drug: Metformin Hydrochloride Sustained-release Tablets
Normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT04756128
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)
Study: NCT04756128
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension.
Study: NCT04622761
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)
Study: NCT05346848
Drug: Association of darolutamide and EBRT
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD
Study: NCT06193148
Drug: Jaktinib
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Jaktinib orally for single dose